Slingshot Insights | Fold Overview

FOLD Overview

Upcoming Projects (FOLD)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (FOLD)

Discussing Paradigm Therapeutics' acquisition of Amicus Therapeutics' SD-101 (developing investigational cream as a whole-body therapy in all forms of EB) after failure to meet primary and key goals in the Phase 3 ESSENCE clinical trial
Tickers: PARADIGM BIOPHARMACEURICALS, FOLD
Executed On: Oct 03, 2023 at 01:00 PM EDT
Discussing the potential of enzyme replacement therapies such as Sanofi's Nexviazyme (avalglucosidase alfa-ngpt) and Amicus Therapeutics' Pombiliti + Opfolda (AT-GAA) in late-onset Pompe disease with a Genetic Counselor.
Tickers: FOLD, SNY
Executed On: Jul 13, 2023 at 01:00 PM EDT
Discussing enzyme replacement therapies such as Sanofi's Nexviazyme (avalglucosidase alfa-ngpt) and Amicus Therapeutics's Pombiliti + Opfolda(AT-GAA) with a specialist who treats patients with late-onset Pompe disease.
Tickers: FOLD, SNY
Executed On: Jun 13, 2023 at 11:00 AM EDT
Discussing the potential of AT-GAA (cipaglucosidase alfa/miglustat) in treating Pompe Patients, with a focus on the Propel study results
Ticker: FOLD
Executed On: Jan 24, 2022 at 11:00 AM EST

Upcoming & Overdue Catalysts (FOLD)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (FOLD)

Don’t see a strategic initiative related to the company you care about? Create your own!